Linked Life Data

16401668

Source:http://linkedlifedata.com/resource/pubmed/id/16401668

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2006-6-8
pubmed:abstractText
The present study was undertaken to elucidate the effects of repeated treatment with milnacipran, a serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor (SNRI), on the synaptic plasticity in the hippocampal CA1 field, focusing on the interaction between the serotonergic and noradrenergic system. Repeated treatment with milnacipran (30 mg/kg, i.p. after 30 mg/kg, p.o. x 14 days) completely restored the suppression of the long-term potentiation (LTP) induced by single milnacipran treatment (30 mg/kg, i.p.). Single and repeated milnacipran increased to a similar extent extracellular NA in the hippocampus. Single milnacipran increased extracellular 5-HT and this effect tended to be enhanced by repeated treatment. The restoration of LTP and facilitation of the 5-HT level were not shown after repeated treatment with a selective 5-HT reuptake inhibitor (SSRI) fluvoxamine (30 mg/kg, p.o. x 14 days). These results suggest that milnacipran-induced restoration of LTP suppression is responsible for the enhancement of 5-HT neurotransmission, which appears to be associated with noradrenergic neuronal activity. In addition, the 5-HT1A receptor agonist tandospirone-induced suppression of LTP was completely blocked by repeated treatment with milnacipran, indicating the possibility that this reversal effect is due to the functional changes in postsynaptic 5-HT1A receptors. Taken together, the present data suggest that the interaction between the serotonergic and noradrenergic mechanism play an important role in the modulation of synaptic plasticity caused by repeated treatment with milnacipran, which may be implicated in the therapeutic effects of SNRI on psychiatric disorders.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0269-8811
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
562-9
pubmed:meshHeading
pubmed-meshheading:16401668-Adrenergic Uptake Inhibitors, pubmed-meshheading:16401668-Animals, pubmed-meshheading:16401668-Antidepressive Agents, pubmed-meshheading:16401668-Brain Chemistry, pubmed-meshheading:16401668-Cyclopropanes, pubmed-meshheading:16401668-Electrophysiology, pubmed-meshheading:16401668-Extracellular Space, pubmed-meshheading:16401668-Hippocampus, pubmed-meshheading:16401668-Long-Term Potentiation, pubmed-meshheading:16401668-Male, pubmed-meshheading:16401668-Microdialysis, pubmed-meshheading:16401668-Neuronal Plasticity, pubmed-meshheading:16401668-Norepinephrine, pubmed-meshheading:16401668-Rats, pubmed-meshheading:16401668-Rats, Wistar, pubmed-meshheading:16401668-Receptor, Serotonin, 5-HT1A, pubmed-meshheading:16401668-Serotonin, pubmed-meshheading:16401668-Serotonin Uptake Inhibitors, pubmed-meshheading:16401668-Synapses, pubmed-meshheading:16401668-Synaptic Transmission
pubmed:year
2006
pubmed:articleTitle
Electrophysiological and neurochemical characterization of the effect of repeated treatment with milnacipran on the rat serotonergic and noradrenergic systems.
pubmed:affiliation
Department of Anesthesiology and Critical Care Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
pubmed:publicationType
Journal Article